Spexis AG agrees with Basilea Pharmaceutica to provide a preclinical program of antibiotics targeting Gram
Spexis AG , a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, announced that it has entered into an asset purchase agreement with Basilea Pharmaceutica Ltd, Allschwil wherein Basilea will acquire from Spexis a preclinical program of antibiotics from a novel class targeting Gram-negative bacteria, including multidrug-resistant strains
The assets sold to Basilea are macrocyclic antibiotics developed within Spexis’ Outer Membrane Protein Targeting Antibiotics (OMPTA) program which selectively disrupt the lipopolysaccharide transport bridge, an essential structure in Gram-negative bacteria. This results in a loss of the integrity of the outer cell membrane, intracellular accumulation of lipopolysaccharides and killing of the bacteria. Activity has been shown in vitro and in vivo against Enterobacteriaceae such as E. coli and K. pneumoniae, including strains resistant to beta-lactams and colistin, an antibiotic regarded as last-resort therapy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
